20 Great Companies with Cheap Stocks
A great, durable business model isn't enough to get into this 20-member club.
A great, durable business model isn't enough to get into this 20-member club.
As investors, there are few things we like more than companies with durable competitive advantages selling at steep discounts to their value. At Morningstar, we have an index called the Morningstar Wide Moat Focus. This index is comprised of the cheapest wide-moat firms in our 2,000-plus stock coverage universe. These are the firms with the strongest competitive advantages in their industries and the ones where we believe the advantages will persist for years to come. Less than 10% of the companies that we follow have built a competitive advantage that is durable enough to qualify for our wide-moat rating, limiting our wide-moat universe to 174 firms. Still, that's not good enough to be included in our index, because we don't want to simply buy great firms--we want to buy them at bargain basement prices. So we limit the index to the 20 cheapest (based on price/fair value) wide-moat firms. And every three months, we reconstitute the list so that, once again, only the 20 cheapest wide-moat firms get in and we readjust the holdings to equal-weight the index. It's a pretty exclusive club, and its performance shows that it pays to wait.
The most recent index, before its reconstitution, ran from March 23 until June 19 and racked up a 40.6% return over that period. Through July 6, the index has increased 14% year-to-date and has a 0.5% annualized return over a three-year period. These returns far outpace the market's return in the same periods.
As long-term investors know, it often takes several quarters if not years for an investment idea to play out, for the market to reflect a stock's intrinsic worth. American Express (AXP) and Legg Mason are examples of this: each stock has been included in the index for several quarters, typically logging a negative return; however, in the prior three months both firms saw their stock prices increase considerably, and the two stocks had the highest contribution to the index's 40.6% return. American Express logged a 104% return but is still the cheapest wide moat in the current portfolio. Sometimes--too rarely it seems--a cheap firm appears on the radar screen and then Mr. Market quickly rationalizes its valuation. Such was the case with Advisory Board , which appeared for the first time in the prior portfolio, returned 70% over three months, and no longer qualified for the current portfolio.
While past performance cannot predict future returns, we believe that our "buy great firms with significantly undervalued stocks" strategy will continue to work over the long term. Despite the current economic environment--as confusing as it is with its rising unemployment rates, mounting budget deficits, and yet sprouting "green shoots" here and there--strong firms should continue to outperform weaker ones (and the broader market) over the long term.
Current Constituents of Morningstar Wide Moat Focus Index* | |||||
Company | Fair Value Estimate | Price/Fair Value | Fair Value Uncertainty | Portfolio Weighting | New to Portfolio? |
American Express Company (AXP) | $54.00 | 42% | High | 4.6% | |
IMS Health, Inc. | $26.00 | 47% | Medium | 4.7% | Yes |
St. Joe Corporation (JOE) | $50.00 | 47% | High | 5.1% | |
Time Warner Cable, Inc. A | $60.00 | 50% | Medium | 5.1% | Yes |
Applied Materials (AMAT) | $22.00 | 50% | Medium | 4.9% | Yes |
International Speedway Corporation A | $51.00 | 50% | Medium | 4.8% | |
Zimmer Holdings, Inc. (ZMH) | $78.00 | 51% | Medium | 5.1% | |
Lowe's Companies, Inc. (LOW) | $36.00 | 52% | Medium | 5.0% | |
Comcast Corporation | $25.00 | 52% | Medium | 5.3% | Yes |
Paychex, Inc. (PAYX) | $46.00 | 53% | Medium | 4.6% | |
Stryker Corporation (SYK) | $72.00 | 53% | Low | 5.0% | |
Harley-Davidson, Inc. (HOG) | $28.00 | 54% | High | 5.0% | |
The Western Union Company (WU) | $28.00 | 55% | Medium | 4.9% | |
US Bancorp (USB) | $31.00 | 55% | High | 4.9% | |
Pfizer Inc. (PFE) | $26.00 | 56% | Medium | 5.2% | Yes |
KLA-Tencor Corporation (KLAC) | $45.00 | 57% | Medium | 5.0% | |
Linear Technology | $38.00 | 60% | Medium | 5.1% | Yes |
Merck & Co., Inc. (MRK) | $46.00 | 60% | Medium | 5.6% | Yes |
RenaissanceRe Holdings, Ltd. (RNR) | $77.00 | 61% | High | 4.9% | yes |
Eli Lilly & Company (LLY) | $54.00 | 62% | Medium | 5.1% | Yes |
* Data as of July 7, 2009 |
The current portfolio contains nine newcomers--firms that weren't cheap enough to include in the prior portfolio. Three of them ( Merck (MRK), Pfizer (PFE), and Eli Lilly (LLY)) are global pharmaceutical firms. Senior Analyst Damien Conover explains why all three are being undervalued in the marketplace and why he believes they offer compelling investment opportunities: "The market's short-term focus on patent losses and fear of U.S. health-care reform have weighed heavily on pharmaceutical companies' valuations. However, over the long term, we believe pharmaceutical companies' pipelines will create the next generation of blockbusters mitigating the near-term generic competition. Further, we expect a relatively neutral impact from U.S. health-care reform as we believe new reform will increase drug usage, offsetting modest price concessions." Once again, time arbitrage and a long-term investment horizon look set to trump short-term concerns.
There are also two cable firms that are new to the index: Time Warner Cable and Comcast . Associate Director Michael Hodel recently wrote an article explaining how we believe the market is misvaluing the long-term competitive strengths of cable operators' networks. Once again, our index is anticipating that over the long term the market will get the valuation right, generating solid returns for investors with the patience to wait.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.